8-K: ESSA Pharma Announces Positive Phase 1/2 Clinical Data for Masofaniten in Prostate Cancer Treatment

ESSA Pharma reported promising updated data from its Phase 1/2 study of masofaniten combined with enzalutamide, showing significant PSA reductions in patients with metastatic castration-resistant prostate cancer.

Summary

• ESSA Pharma presented updated data from its Phase 1/2 study of masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 ASCO Genitourinary Cancers Symposium.
• The study evaluated the combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
• The combination of masofaniten and enzalutamide was well-tolerated, with most adverse events being Grade 1 or 2.
• The recommended Phase 2 doses were identified as 600 mg of masofaniten twice daily and 160 mg of enzalutamide once daily.
• In the efficacy evaluable patients, 81% achieved a PSA90 reduction, 69% achieved PSA90 in less than 90 days, and 63% achieved a PSA level of less than 0.2 ng/mL.
• The median time to PSA progression is currently at 16.6 months, though the data is still maturing.
• A Phase 2 dose expansion study is underway to compare the combination therapy to enzalutamide alone.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data with high efficacy and good tolerability, suggesting a strong potential for the drug. The sentiment is very positive, but tempered by the fact that the data is still maturing and the Phase 2 study is ongoing.

Positives

• The combination of masofaniten and enzalutamide is well-tolerated.
• The therapy shows rapid, deep, and durable reductions in PSA levels.
• A high percentage of patients achieved significant PSA reductions.
• The median time to PSA progression is encouraging at 16.6 months.
• The study has identified recommended Phase 2 doses for the combination therapy.

Negatives

• One patient experienced a Grade 3 rash, which was deemed probably related to the combination therapy.
• Enzalutamide reduces masofaniten exposure, although twice daily dosing of masofaniten appears to mitigate this.

Risks

• The data is still maturing, and the long-term benefits of masofaniten are yet to be fully evaluated.
• The Phase 2 study is still underway, and the results of the head-to-head comparison with enzalutamide alone are pending.
• There are inherent risks and uncertainties associated with clinical trials and regulatory approvals.
• The company is subject to medical, scientific, business, economic, competitive, political and social uncertainties and contingencies.

Future Outlook

The company is looking forward to evaluating the potential long-term benefits of masofaniten in patients with mCRPC and will provide future updates on the Phase 1/2 and Phase 2 studies.

Management Comments

• The Phase 2 dose expansion head-to-head portion of the study is underway and is designed to evaluate the proportion of patients with a PSA decline on combination therapy compared to single agent enzalutamide, said David Parkinson, MD, President and CEO of ESSA.
• We look forward to evaluating the potential long-term benefits of masofaniten in patients with metastatic castration-resistant prostate cancer and to providing future updates.

Industry Context

This announcement is significant in the prostate cancer treatment landscape as it presents a novel approach using a first-in-class N-terminal domain androgen receptor inhibitor. The results are being presented at a major industry conference, the ASCO Genitourinary Cancers Symposium, indicating the importance of the findings.

Comparison to Industry Standards

• The PSA reduction rates of 81% achieving PSA90, 69% achieving PSA90 in less than 90 days, and 63% achieving PSA <0.2ng/mL are very promising compared to standard treatments for mCRPC.
• Common treatments such as enzalutamide alone typically show lower PSA reduction rates and shorter times to progression.
• The median time to PSA progression of 16.6 months is also encouraging, as many current therapies have shorter progression-free survival times.
• The results are comparable to or better than some other novel therapies in development for mCRPC, such as those targeting the androgen receptor pathway.

Stakeholder Impact

• Shareholders will likely view the positive clinical data favorably.
• Patients with mCRPC may benefit from this new treatment option.
• The company's employees are working on a promising therapy.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The Phase 2 dose expansion study is underway and will compare the combination therapy to enzalutamide alone.
• The company will continue to enroll patients in the Phase 2 study at approximately 25 sites in the USA, Canada, and Australia, with expansion to European sites in progress.
• The company will provide future updates on the Phase 1/2 and Phase 2 studies.

Key Dates

Keywords

masofaniten, prostate cancer, mCRPC, enzalutamide, PSA, clinical trial, androgen receptor, Phase 1/2, Phase 2, cancer therapy